WARREN, N.J., September 23, 2016 – MonoSol Rx develops and manufactures FDA-approved pharmaceutical film products. The company licenses its PharmFilm® drug delivery technology to improve patient treatment and to address unmet needs. MonoSol Rx was notified last night of a civil complaint filed earlier yesterday by thirty five U.S. states and the District of Columbia, alleging violations of federal and state antitrust and consumer protection laws related to Suboxone® (buprenorphine and naloxone) sublingual film.
“We believe that the allegations in the complaint are wholly without merit and the suit is both factually and legally deficient. As a small innovative company with R&D in New Jersey and manufacturing in Indiana, we are proud of our patented technology and the value it has brought to patients and caregivers” said Keith Kendall, CEO of MonoSol Rx. “I think it is important to add that Suboxone sublingual film is a product which has saved countless lives since its approval by the FDA in 2010.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm® can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx’s leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, please visitwww.monosolrx.com.